Imfinzi

Durvalumab, the active ingredient in Imfinzi, is a PD‑L1 inhibitor presented as an injectable solution for intravenous infusion for use in oncology patients. It is indicated for the treatment of certain lung and bladder cancers in adult patients.

GNH USA supplies Imfinzi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for biologic products. Clients benefit from reliable delivery, regulatory support, and comprehensive product documentation.

Imfinzi is used in immunotherapy for cancers that express the PD‑L1 pathway.

Stage III non‑small cell lung cancer (NSCLC) after chemoradiotherapy: improves progression‑free survival in adult patients. Extensive‑stage small cell lung cancer (ES‑SCLC) in combination with chemotherapy: extends overall survival when added to standard regimens. Urothelial carcinoma (advanced or metastatic): provides an additional treatment option for patients with disease progression after prior therapy. Stage III NSCLC (post‑chemoradiotherapy) maintenance: reduces risk of disease recurrence and prolongs survival. Advanced urothelial carcinoma after platinum‑based chemotherapy: offers an alternative immunotherapy option for patients with disease progression.

Durvalumab may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Nausea: sensation of needing to vomit. - Infusion‑related reactions: fever, chills, or flushing during administration.

Serious or Rare Side Effects: - Pneumonitis: inflammation of lung tissue that can impair breathing. - Hepatitis: liver inflammation that may elevate liver enzymes. - Severe colitis: inflammation of the colon causing abdominal pain and diarrhea.

When using Imfinzi, clinicians should observe several safety measures.

- Monitor for immune‑mediated adverse events: watch for signs of pneumonitis, hepatitis, colitis, endocrinopathies. - Assess liver function tests regularly: elevated enzymes may indicate hepatic toxicity. - Evaluate pulmonary symptoms: cough or shortness of breath may signal lung inflammation. - Review patient’s autoimmune history: pre‑existing conditions may worsen with therapy. - Avoid live vaccines during treatment: immunosuppression can increase infection risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Durvalumab can interact with other medicines; awareness of major and moderate interactions helps manage risk.

Major Interactions (Avoid): - Concurrent use with other immune checkpoint inhibitors: may increase risk of severe immune‑related toxicity. - Live attenuated vaccines: can cause uncontrolled infection due to immune suppression. - High‑dose systemic steroids: may diminish therapeutic efficacy of durvalumab.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, DOACs): increased bleeding risk if thrombocytopenia occurs. - CYP450 substrates: monitor levels as immune modulation may affect metabolism. - Other immunosuppressive agents (e.g., azathioprine): may reduce antitumor response.